临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2014年
10期
838-840
,共3页
卵巢癌%紫杉醇%顺铂%热灌注化疗
卵巢癌%紫杉醇%順鉑%熱灌註化療
란소암%자삼순%순박%열관주화료
Ovarian cancer%Paclitaxel%Cisplatin%Perfusion chemotherapy
目的：观察紫杉醇联合顺铂腹腔热灌注化疗治疗晚期卵巢癌的临床疗效。方法78例晚期卵巢癌患者随机分为两组，观察组（ n=40例）采用紫杉醇联合顺铂腹腔热灌注化疗治疗，对照组（ n=38例）采用紫杉醇联合顺铂静脉注射化疗治疗。比较两组临床疗效、无进展生存期、中位生存期、1年生存率、2年生存率、3年生存率及不良反应等。结果观察组腹腔热灌注化疗有效率（80.0％）明显高于对照组静脉滴注化疗有效率（63.2％）（ P <0.05）；观察组无进展生存期、中位生存期、1年生存率、2年生存率和3年生存率均明显高于对照组（ P <0.05）；观察组毒副反应发生率（42.5％）明显低于对照组（60.5％）。结论紫杉醇联合顺铂腹腔热灌注化疗治疗晚期卵巢癌疗效显著，可明显提高患者生存期及生存率，不良反应较少，值得临床推广应用。
目的：觀察紫杉醇聯閤順鉑腹腔熱灌註化療治療晚期卵巢癌的臨床療效。方法78例晚期卵巢癌患者隨機分為兩組，觀察組（ n=40例）採用紫杉醇聯閤順鉑腹腔熱灌註化療治療，對照組（ n=38例）採用紫杉醇聯閤順鉑靜脈註射化療治療。比較兩組臨床療效、無進展生存期、中位生存期、1年生存率、2年生存率、3年生存率及不良反應等。結果觀察組腹腔熱灌註化療有效率（80.0％）明顯高于對照組靜脈滴註化療有效率（63.2％）（ P <0.05）；觀察組無進展生存期、中位生存期、1年生存率、2年生存率和3年生存率均明顯高于對照組（ P <0.05）；觀察組毒副反應髮生率（42.5％）明顯低于對照組（60.5％）。結論紫杉醇聯閤順鉑腹腔熱灌註化療治療晚期卵巢癌療效顯著，可明顯提高患者生存期及生存率，不良反應較少，值得臨床推廣應用。
목적：관찰자삼순연합순박복강열관주화료치료만기란소암적림상료효。방법78례만기란소암환자수궤분위량조，관찰조（ n=40례）채용자삼순연합순박복강열관주화료치료，대조조（ n=38례）채용자삼순연합순박정맥주사화료치료。비교량조림상료효、무진전생존기、중위생존기、1년생존솔、2년생존솔、3년생존솔급불량반응등。결과관찰조복강열관주화료유효솔（80.0％）명현고우대조조정맥적주화료유효솔（63.2％）（ P <0.05）；관찰조무진전생존기、중위생존기、1년생존솔、2년생존솔화3년생존솔균명현고우대조조（ P <0.05）；관찰조독부반응발생솔（42.5％）명현저우대조조（60.5％）。결론자삼순연합순박복강열관주화료치료만기란소암료효현저，가명현제고환자생존기급생존솔，불량반응교소，치득림상추엄응용。
Objective To observe the clinical curative effect of paclitaxel combined with cisplatin intraperitoneal chemotherapy in the treatment of advanced ovarian cancer. Methods 78 patients with advanced ovarian cancer were randomly divided into 2 groups,the observation group and the control group. The observation group( n=40 cases)was treated with paclitaxel combined with cisplatin intraperitoneal chemotherapy treatment. The control group( n=38 cases)was treated with paclitaxel combined with cisplatin chemotherapy by intravenous injection. The clini-cal efficacy,progression free survival,median survival time,survival rate of 1 years,2 years survival rate,3 year survival rate and adverse reaction of two groups were observed and compared. Results The efficiency of observation group( intraperitoneal hyperthermic perfusion chemotherapy) (80%)was significantly higher than that of control group(intravenous chemotherapy)(63. 2%)( P <0. 05). The progression free survival, median survival time,survival rate of 1 years,2 years survival rate and 3 year survival rate of observation group were significantly higher than those of the control group( P <0. 05). The incidence rate of side reaction in observation group(42. 5%)was significantly lower than that of the con-trol group(60. 5%). Conclusion The treatment of paclitaxel combined with cisplatin intraperitoneal hyperthermic perfusion chemotherapy for advanced ovarian cancer had a significantly curative effect. This method could significantly improve the survival duration and survival rate,less ad-verse reactions. It was worthy of clinical application.
